Amphastar Pharmaceuticals (FRA:29A) Accounts Payable & Accrued Expense : €230.7 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals Accounts Payable & Accrued Expense?

Amphastar Pharmaceuticals's quarterly accounts payable & accrued expense declined from Sep. 2023 (€237.8 Mil) to Dec. 2023 (€202.7 Mil) but then increased from Dec. 2023 (€202.7 Mil) to Mar. 2024 (€230.7 Mil).

Amphastar Pharmaceuticals's annual accounts payable & accrued expense declined from Dec. 2021 (€87.3 Mil) to Dec. 2022 (€83.8 Mil) but then increased from Dec. 2022 (€83.8 Mil) to Dec. 2023 (€202.7 Mil).

Amphastar Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Amphastar Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Accounts Payable & Accrued Expense Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

71.18

79.39

87.28

83.84

202.72

Amphastar Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															93.85	217.12	237.82	202.72	230.74

Amphastar Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Amphastar Pharmaceuticals (FRA:29A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

AMPH:USA 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals (FRA:29A) Headlines

No Headlines